SCHEMBL4331630

SCHEMBL4331630

COCCCN(N=Cc1ccc(COc2ccc(Cl)c(Cl)c2)o1)C(N)=S

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.39
KDM4E B2RXH2 2/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KMT2A Q03164 6/20 0.34
MEN1 O00255 4/20 0.34
HTT P42858 1/20 0.34
POLB P06746 3/20 0.34
DAO P14920 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 1/20 0.34
EYA2 O00167 1/20 0.34
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4331501 0.83 KMT2A (0.53) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL4332719 0.83 MAPT (0.39) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL4326576 0.80 SMN1; SMN2 (0.39) MAPTALDH1A1HPGDNPSR1KMT2A
SCHEMBL4331625 0.76 MAPT (0.54) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL4331633 0.76 MAPT (0.54) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL4334398 0.75 POLB (0.48) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL4336892 0.74 ALDH1A1 (0.61) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL4336889 0.74 ALDH1A1 (0.61) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL4332722 0.71 MAPT (0.50) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL13612327 0.71 MAPT (0.50) MAPTKDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885KDM4E 3010/4885NPC1 1680/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885KDM4E 2338/4885NPC1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.